Category
Growth hormone
GHRH and GHRP analogues — the compounds that prompt the body to release its own growth hormone rather than supplying it. A split group: a couple carry approved products and real trial records, and the rest are known mainly from the clinic and gym market.
What the record holds for this category
8
Compounds tracked
2
With an FDA-approved product
4
With no registered human study
27
Registered studies, all members
Every compound in this category
Ordered by how many people read the Wikipedia article each month, which measures attention and nothing else. The evidence column is what is actually known.
| Compound | FDA status | Human studies | Evidence | Readership |
|---|---|---|---|---|
| CJC-1295 | Research only | 1 | CPhase 1 or 2 only | 10,462 |
| Tesamorelin | Approved | 18 | AAn approved product exists | 8,990 |
| Sermorelin | Approved | 0 | EApproved, no registry record | 8,297 |
| MK-677 | Research only | 6 | CPhase 1 or 2 only | 8,291 |
| Ipamorelin | Research only | 2 | CPhase 1 or 2 only | 6,559 |
| GHRP-6 | Research only | 0 | XNo registered human study | 1,552 |
| GHRP-2 | Research only | 0 | XNo registered human study | 73 |
| Hexarelin | Research only | 0 | XNo registered human study | 30 |
Compare within this category
These pairs are the most-read members, picked mechanically. Pairing is not a recommendation and says nothing about which is preferable.
Reading on these compounds
Categories are editorial groupings by mechanism — they are not medical classifications, and membership is not a claim that a compound does what the group name suggests. Study counts include only trials whose registered intervention names the compound. Collected 2026-08-02 from ClinicalTrials.gov and Drugs@FDA. How this is put together.